Guggenheim reiterates Eli Lilly stock rating on positive trial data By Investing.com

Eli Lilly reported positive Phase 3 ACHIEVE-4 results for Foundayo, showing a 16% reduction in major adverse cardiovascular events versus insulin glargine and no hepatic safety signal. The company said it plans to submit Foundayo to the FDA for type 2 diabetes by the end of Q2, reinforcing a potential label expansion path, while analysts at Guggenheim, Leerink, and BMO reiterated Buy/Outperform ratings with price targets of $1,163, $1,296, and $1,300. Lilly also highlighted strong fundamentals, including 45% revenue growth over the last 12 months and a Piotroski Score of 9.

Analysis

The market is still underestimating how much optionality Lilly has created by pairing a near-term obesity franchise with a second, cleaner oral diabetes thesis. The important second-order effect is not just incremental revenue; it is payer behavior. If an oral GLP-1 can demonstrate durable cardio-metabolic benefit with a more manageable safety package, it widens the addressable pool beyond the current injectable/coverage-constrained cohort and could force rivals to compete on adherence and access rather than efficacy alone.

Near term, the biggest winner is Lilly’s commercial negotiating power. Positive cardiovascular and hepatic read-throughs reduce the odds of a slow, labeling-driven launch and should compress the usual “data-overhang” discount that gets applied to new metabolic assets. That matters because the stock is trading like a premium quality compounder, but the earnings power from an oral platform plus obesity remains underappreciated versus the headline multiple.

The contrarian risk is that the market may be too enthusiastic about timing. Regulatory clarity is not the same as commercial clarity: formulary wins, Medicare coverage, and branding decisions will determine how much of the theoretical demand converts into 2025-2026 revenue. There is also execution risk that the oral product cannibalizes some future injectable mix while failing to fully expand total market size, which would cap upside if the launch is judged only against the current obesity narrative.

For competitors, the message is more threatening than the headline suggests. Lilly is building a data package that pressures the entire GLP-1 ecosystem toward broader outcomes evidence and lowers the strategic value of “me-too” incretin programs without differentiated tolerability or access. That should keep multiple compression pressure on lesser-positioned obesity and diabetes names over the next 6-12 months, especially if investors rotate toward the franchise with the clearest path to label expansion and payer leverage.

Key Decisions for Investors

• Stay long LLY into the next 3-6 months; use dips tied to regulatory/process noise as add points, because the main catalyst is not a single readout but a multi-quarter de-risking of the oral platform and label expansion path.
• Consider a pair trade: long LLY / short a basket of higher-beta obesity/diabetes peers with weaker payer positioning or less differentiated pipelines over the next 6-12 months; the relative thesis is stronger than the outright beta trade.
• Buy LLY call spreads 6-12 months out rather than stock if you want upside convexity with controlled downside; the setup is favorable if the market begins assigning launch probability to the oral franchise before revenue shows up.
• If already long, hedge near-term event risk with downside puts around regulatory/coverage milestones; the main reversal risk is not efficacy, but a slower-than-expected reimbursement or launch cadence over the next 1-2 quarters.
• Do not short LLY on valuation alone; the risk/reward is poor because incremental clinical de-risking can re-rate the stock faster than earnings revisions, especially if market participants start modeling category-share expansion rather than just EBITDA multiples.